{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T23:54:54Z","timestamp":1768348494110,"version":"3.49.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure: European Journal of Epilepsy"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.seizure.2022.06.015","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T20:21:25Z","timestamp":1656361285000},"page":"103-108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Perampanel as adjunctive therapy in drug resistant epilepsy in adolescents and children waiting for epilepsy surgery: A multicenter observational study in Thailand"],"prefix":"10.1016","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9814-3867","authenticated-orcid":false,"given":"Piradee","family":"Suwanpakdee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burachat","family":"Saksritavee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0695-0950","authenticated-orcid":false,"given":"Napakjira","family":"Likasitthananon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thitiwan","family":"Simasathien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tayard","family":"Deesudchit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0500-6116","authenticated-orcid":false,"given":"Chaiyos","family":"Khongkhatithum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4965-1715","authenticated-orcid":false,"given":"Sorawit","family":"Viravan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charcrin","family":"Nabangchang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.seizure.2022.06.015_bib0001","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1684\/epd.2015.0736","article-title":"Incidence, prevalence and aetiology of seizures and epilepsy in children","volume":"17","author":"Camfield","year":"2015","journal-title":"Epileptic Disord"},{"issue":"30","key":"10.1016\/j.seizure.2022.06.015_bib0002","doi-asserted-by":"crossref","first-page":"e16402","DOI":"10.1097\/MD.0000000000016402","article-title":"Risk factors for drug-resistant epilepsy: a systematic review and meta-analysis","volume":"98","author":"Xue-Ping","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"17","key":"10.1016\/j.seizure.2022.06.015_bib0003","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1212\/WNL.0000000000011839","article-title":"Incidence and prevalence of drug-resistant epilepsy: a systematic review and meta-analysis","volume":"96","author":"Sultana","year":"2021","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.seizure.2022.06.015_bib0004","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"issue":"12","key":"10.1016\/j.seizure.2022.06.015_bib0005","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1111\/epi.14596","article-title":"The epidemiology of drug-resistant epilepsy: a systematic review and meta-analysis","volume":"59","author":"Kalilani","year":"2018","journal-title":"Epilepsia"},{"issue":"23","key":"10.1016\/j.seizure.2022.06.015_bib0006","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1212\/WNL.0000000000003407","article-title":"What can we do for people with drug-resistant epilepsy? The 2016 Wartenberg Lecture","volume":"87","author":"Engel","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2022.06.015_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108222","article-title":"Identifying key unmet needs and value drivers in the treatment of focal-onset seizures (FOS) in patients with drug-resistant epilepsy (DRE) in Spain through Multi-Criteria Decision Analysis (MCDA)","volume":"122","author":"Villanueva","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2022.06.015_bib0008","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.2147\/NDT.S256699","article-title":"Clinical management of drug resistant epilepsy: a review on current strategies","volume":"17","author":"Guery","year":"2021","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.seizure.2022.06.015_bib0009","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.2147\/NDT.S84852","article-title":"Managing drug-resistant epilepsy: challenges and solutions","volume":"12","author":"Dalic","year":"2016","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.seizure.2022.06.015_bib0010","unstructured":"Food and Drug Administration. Fycompa \u2013 Full Prescribing Information. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/202834s016,208277s004lbl.pdf (Last Accessed 23 February 2022)."},{"key":"10.1016\/j.seizure.2022.06.015_bib0011","unstructured":"European Medicines Agency (EMA). Perampanel (Fycompa): Summary of Product Characteristics. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/fycompa-epar-product-information_en.pdf (Last Accessed 23 February 2022)."},{"issue":"10","key":"10.1016\/j.seizure.2022.06.015_bib0012","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s40263-013-0091-9","article-title":"Systematic review and meta-analysis of the efficacy and safety of perampanel in the treatment of partial-onset epilepsy","volume":"27","author":"Hsu","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.seizure.2022.06.015_bib0013","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jns.2018.04.017","article-title":"Perampanel as adjunctive therapy in highly refractory epilepsies: real-world data from an Italian tertiary care epilepsy centre","volume":"390","author":"Morano","year":"2018","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.seizure.2022.06.015_bib0014","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.yebeh.2016.10.020","article-title":"A two-year retrospective evaluation of perampanel in patients with highly drug-resistant epilepsy and cognitive impairment","volume":"66","author":"Huber","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2022.06.015_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.116903","article-title":"The efficacy of perampanel as adjunctive therapy in drug-resistant focal epilepsy in a \"real world\" context: focus on temporal lobe epilepsy","volume":"415","author":"Pascarella","year":"2020","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.seizure.2022.06.015_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.107935","article-title":"Efficacy and tolerability of adjuvant perampanel: an Australian multicenter real-world observational study in refractory focal and generalized epilepsy syndromes","volume":"119","author":"Sagar","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2022.06.015_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108073","article-title":"Perampanel treatment in highly drug-resistant epilepsies including nonsurgical candidates and failed surgery","volume":"121","author":"Limotai","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2022.06.015_bib0018","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.seizure.2019.12.024","article-title":"The efficacy of perampanel in young children with drug-resistant epilepsy","volume":"75","author":"Chang","year":"2020","journal-title":"Seizure"},{"issue":"2","key":"10.1016\/j.seizure.2022.06.015_bib0019","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1055\/s-0035-1546276","article-title":"Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies: first experiences","volume":"46","author":"Bir\u00f3","year":"2015","journal-title":"Neuropediatrics"},{"issue":"9","key":"10.1016\/j.seizure.2022.06.015_bib0020","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1177\/0883073817709195","article-title":"Clinical experience with perampanel for refractory pediatric epilepsy in one Canadian center","volume":"32","author":"Datta","year":"2017","journal-title":"J Child Neurol"},{"issue":"7","key":"10.1016\/j.seizure.2022.06.015_bib0021","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3345\/kjp.2018.06863","article-title":"Efficacy and tolerability of adjunctive perampanel treatment in children under 12 years of age with refractory epilepsy","volume":"62","author":"Yun","year":"2019","journal-title":"Korean J Pediatr"},{"key":"10.1016\/j.seizure.2022.06.015_bib0022","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.yebeh.2018.06.033","article-title":"Efficacy and tolerability of perampanel in children and adolescents with pharmacoresistant epilepsy: The first real-world evaluation in Asian pediatric neurology clinics","volume":"85","author":"Lin","year":"2018","journal-title":"Epilepsy Behav"},{"issue":"4","key":"10.1016\/j.seizure.2022.06.015_bib0023","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.seizure.2022.06.015_bib0024","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1177\/0883073819827407","article-title":"Adjunctive perampanel oral suspension in pediatric patients from\u2265 2 to < 12 years of age with epilepsy: pharmacokinetics, safety, tolerability, and efficacy","volume":"34","author":"Renfroe","year":"2019","journal-title":"J Child Neurol"},{"issue":"9","key":"10.1016\/j.seizure.2022.06.015_bib0025","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11910-016-0678-x","article-title":"Pharmacological treatment of drug-resistant epilepsy in adults: a practical guide","volume":"16","author":"Brodie","year":"2016","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.seizure.2022.06.015_bib0026","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1001\/jamaneurol.2014.808","article-title":"Effectiveness of antiepileptic drug combination therapy for partial-onset seizures based on mechanisms of action","volume":"71","author":"Margolis","year":"2014","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.seizure.2022.06.015_bib0027","doi-asserted-by":"crossref","first-page":"14","DOI":"10.14581\/jer.19002","article-title":"Antiepileptic drug therapy in patients with drug-resistant epilepsy","volume":"9","author":"Park","year":"2019","journal-title":"J Epilepsy Res"},{"key":"10.1016\/j.seizure.2022.06.015_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.674483","article-title":"The pharmacoresistant epilepsy: an overview on existant and new emerging therapies","volume":"12","author":"Fattorusso","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.seizure.2022.06.015_bib0029","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.2147\/DDDT.S122404","article-title":"Spotlight on perampanel in the management of seizures: design, development and an update on place in therapy","volume":"11","author":"Faulkner","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.seizure.2022.06.015_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108069","article-title":"Perampanel effectiveness and tolerability in patients with epilepsy at long-term follow-up","volume":"121","author":"Fernandes","year":"2021","journal-title":"Epilepsy Behav"},{"issue":"4","key":"10.1016\/j.seizure.2022.06.015_bib0031","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ejpn.2015.02.008","article-title":"Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study","volume":"19","author":"Rosenfeld","year":"2015","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.seizure.2022.06.015_bib0032","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.seizure.2017.08.014","article-title":"Effectiveness and tolerability of Perampanel in children, adolescents and young adults with refractory epilepsy: a UK national multicentre study","volume":"52","author":"Swiderska","year":"2017","journal-title":"Seizure"}],"container-title":["Seizure: European Journal of Epilepsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131122001492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131122001492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T02:02:03Z","timestamp":1761012123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131122001492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":32,"alternative-id":["S1059131122001492"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2022.06.015","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perampanel as adjunctive therapy in drug resistant epilepsy in adolescents and children waiting for epilepsy surgery: A multicenter observational study in Thailand","name":"articletitle","label":"Article Title"},{"value":"Seizure: European Journal of Epilepsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2022.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}